Document Detail

Utility of Intra-Aortic Balloon Pump Support for Ventricular Septal Rupture and Acute Mitral Regurgitation Complicating Acute Myocardial Infarction.
MedLine Citation:
PMID:  24035169     Owner:  NLM     Status:  Publisher    
Clinical data on optimal management of mechanical complications of myocardial infarction are lacking. We retrospectively evaluated the effect of intra-aortic balloon pump (IABP) on 30-day survival in patients with postinfarction ventricular septal rupture (VSR, n = 55) or acute mitral regurgitation (MR, n = 26) who developed either cardiogenic shock (n = 46) or severe hemodynamic instability that did not fulfill the criteria of shock (n = 35). IABP was inserted in 83% of the patients with shock and 57% of those without shock. Thirty-five (76%) patients with shock and all unstable patients survived until surgical repair, which was performed within a median (interquartile range) of 1 (1 to 2) and 9 (2 to 18) days from the onset of the complication (p <0.001). All patients who did not undergo the operation died within 3 days. Although MR presented more acutely, the patients' outcomes were similar to those with VSR. IABP support reduced 30-day mortality in the patients with shock (61% vs 100%, p = 0.04) but not in the patients without shock (20% vs 27%, p = 0.7). The benefit of IABP support in the shock cohort was driven mainly by reduction of preoperative mortality (11% vs 88%, p <0.001). Early progression of cardiogenic shock and unperformed surgery were the only independent predictors of 30-day mortality (hazard ratio 3.4, 95% confidence interval 1.5 to 8 and hazard ratio 5.1, 95% confidence interval 2.2 to 11, respectively; p = 0.004 and p <0.001, respectively). In conclusion, we suggest that all patients with postinfarction VSR or acute MR with signs of cardiogenic shock should immediately receive IABP as a bridge to emergent surgical repair. In contrast, hemodynamically unstable patients without shock may be first stabilized by medical therapy, without additional benefit of IABP, before they undergo cardiac surgery.
Jiri Kettner; Marek Sramko; Martin Holek; Jan Pirk; Josef Kautzner
Related Documents :
18053159 - Native cardiac reserve predicts survival in acute post infarction heart failure in mice.
2060839 - The evolution of oxidative stress indicators in the course of myocardial ischemia.
19118249 - Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome pati...
15819299 - Antecedent hypertension interacts with adverse ventricular remodeling after myocardial ...
2060109 - Reversible and irreversible elongation of ischemic, infarcted, and healed myocardium in...
16769909 - Matrix metalloproteinase-7 affects connexin-43 levels, electrical conduction, and survi...
11514489 - Quantitative contrast echocardiographic assessment of collateral derived myocardial per...
8836759 - Absence of the inferior vena cava in a patient with omphalocele: two-dimensional echoca...
1674899 - Limb vascular responsiveness to beta-adrenergic receptor stimulation in patients with c...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-9-12
Journal Detail:
Title:  The American journal of cardiology     Volume:  -     ISSN:  1879-1913     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2013 Sep 
Date Detail:
Created Date:  2013-9-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2013 Elsevier Inc. All rights reserved.
Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. Electronic address:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of extended-release niacin on serum lipids and on endothelial function in adults with sickle ...
Next Document:  Effectiveness and Safety of Spironolactone for Systolic Heart Failure.